{"id":12938,"date":"2026-08-21T14:26:55","date_gmt":"2026-08-21T14:26:55","guid":{"rendered":"https:\/\/facesconsent.com\/blog\/?p=12938"},"modified":"2026-08-21T14:40:09","modified_gmt":"2026-08-21T14:40:09","slug":"how-to-treat-platysma-bands-with-botulinum-toxin","status":"publish","type":"post","link":"https:\/\/facesconsent.com\/blog\/how-to-treat-platysma-bands-with-botulinum-toxin\/","title":{"rendered":"How to Treat Platysma Bands With Botulinum Toxin"},"content":{"rendered":"\n

Ask a room of injectors at any aesthetic clinic<\/mark><\/a> whether neck work with botulinum toxin<\/mark><\/a> is off-label and most hands go up. That answer was correct until May 2025 and has been wrong ever since, which means a significant number of practitioners are either avoiding a treatment they could legitimately offer, or offering it while consenting patients for off-label use that no longer applies to the product they are holding.<\/p>\n\n\n\n

The position is more specific than a simple yes or no, and the specificity is where the risk sits.<\/p>\n\n\n\n

What causes platysma bands in neck ageing<\/h2>\n\n\n\n

The platysma is a broad, thin sheet of muscle that covers the anterior neck and extends up over the lower face. It contracts bidirectionally. The superior portion contributes to facial expression, particularly expressions associated with negative emotion, while the inferior portion draws the skin of the upper neck downward.<\/p>\n\n\n\n

Repeated contraction over years, combined with loss of skin elasticity, produces the vertical cords patients notice. The same downward vector pulls on the lower face, softening jawline definition and contributing to the appearance of jowling and downturned oral commissures. Patients often describe the problem as their jawline rather than their neck, which is worth listening for at consultation.<\/p>\n\n\n\n

The distinction that matters clinically is between bands visible only on contraction and laxity visible at rest. These are different problems with different answers.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Assessing platysma muscle bands before treatment<\/h2>\n\n\n\n

Assessment happens at maximum contraction, with the patient actively grimacing or clenching, not at rest. The licensed indication is written around exactly this: moderate to severe prominence seen at maximum contraction, where severity has an important psychological impact on the patient. Patient selection is built into the marketing authorisation rather than left to preference.<\/p>\n\n\n\n

Neuromodulation addresses the dynamic component. It does not address skin laxity, submental fat, platysmal separation or true cervicomental angle loss. A patient whose bands are prominent at rest, or whose main complaint is a heavy submental region, will be disappointed by injection alone and is a referral or a combination-treatment conversation.<\/p>\n\n\n\n

Two screening points come directly from the current safety guidance. Ask about swallowing difficulty and any history of aspiration, and ask about underlying neurological conditions. Both raise the risk of adverse reactions from spread of effect, and both belong on the medical history in writing rather than in conversation.<\/p>\n\n\n\n

The product information does not recommend use under 18, and phase 3 data in patients over 65 is limited, so both groups warrant a more cautious conversation.<\/p>\n\n\n\n

Is platysma bands Botox licensed in the UK?<\/h2>\n\n\n\n

Yes, for one product. The MHRA granted Botox<\/mark><\/a> a marketing authorisation in May 2025 for the temporary improvement in the appearance of moderate to severe platysma prominence seen at maximum contraction, when the severity has an important psychological impact in adults. It is the first and so far only non-surgical neurotoxin authorised in the UK for this indication, and it sits alongside the glabellar, lateral canthal and forehead line indications in the same summary of product characteristics<\/mark><\/a>.<\/p>\n\n\n\n

The critical point is that a marketing authorisation attaches to a product, not to a molecule. Every other botulinum toxin type A product on the UK market is authorised for facial lines and, in some cases, hyperhidrosis and therapeutic indications, but not for platysma prominence. Practitioners can check any product’s authorised indications against the UK authorised botulinum toxin product information<\/mark><\/a> before treating.<\/p>\n\n\n\n

Treating the platysma with a product that does not carry the indication remains lawful, but it is off-label prescribing. That brings a higher consent standard, a clearly documented clinical justification, and prescriber involvement in that decision rather than a practitioner assuming it. Practices moving this into structured digital records find the off-label rationale easier to evidence later, for the reasons set out in ditching paper for smarter consent in aesthetic practice<\/mark><\/a>.<\/p>\n\n\n\n

Toxin choice and why units never transfer<\/h2>\n\n\n\n

Units are not interchangeable between products. Allergan Units are not equivalent to Speywood Units or to the units of any other preparation, and no conversion ratio is endorsed by any manufacturer or regulator.<\/p>\n\n\n\n

This is the single most dangerous habit to carry into neck work. A practitioner who has internalised a familiar ratio for glabellar treatment and applies it to a platysma protocol written in Allergan Units is not adjusting a dose, they are inventing one. Doses for this indication should be read from the product’s own information each time until they are genuinely known.<\/p>\n\n\n\n

Standard handling rules apply and are worth restating because neck treatment uses more product per session. Reconstituted product is for a single patient in a single session, and unused solution must be inactivated and disposed of as set out in the product information.<\/p>\n\n\n\n

Dosing and placement for platysma neck bands<\/h2>\n\n\n\n

Dosing is determined by how many bands require treatment. The BOTOX 100 Allergan Units summary of product characteristics<\/mark><\/a> sets out three total doses used in the clinical programme: 26 Units for one vertical band per side, 31 Units where one side has a single band and the other has two, and 36 Units for two bands per side.<\/p>\n\n\n\n

The dose is distributed between two targets. Into the upper platysma just below the jawline, 2 Units in 0.05 mL is placed at four sites per side. Along each identified vertical band, 1 Unit in 0.025 mL is placed at five sites, spaced roughly 1 to 2 cm apart down the length of the band.<\/p>\n\n\n\n

Technique specifics reduce the chance of effect spreading where it is not wanted. Identify each band with the patient actively contracting. Pinch the band to isolate the muscle from adjacent structures before injecting. Place all injections superficially and intramuscularly with the needle perpendicular to the skin surface, and keep every injection at least 1 cm inferior to the lower border of the mandible. As with any facial injection, care is needed to avoid intravascular placement.<\/p>\n\n\n\n

Initial treatment should begin at the lowest dose appropriate to the presentation rather than the highest the patient’s band pattern would permit. In the pivotal studies, improvement was significantly greater than placebo by day 14 and remained so through day 120, so patients should be reviewed at two weeks rather than assessed on the day.<\/p>\n\n\n\n

\"Injection<\/figure>\n\n\n\n

What the MHRA botulinum toxin warnings change<\/h2>\n\n\n\n

On 15 July 2026 the MHRA published a <\/mark>drug safety update on iatrogenic botulism<\/mark><\/a> covering all botulinum toxin type A products. The SmPC and patient information leaflet for every UK-authorised product are being strengthened to carry an explicit warning.<\/p>\n\n\n\n

Four risk factors are named, and three of them are directly relevant to neck treatment. Risk is increased where patients have predisposing conditions, specifically underlying neurological disorders or a history of dysphagia or aspiration. It is increased where high doses are used. It is increased where a product is used outside its licensed indications or administered into unapproved sites. And it is increased where counterfeit or unauthorised product is used, which the MHRA’s Criminal Enforcement Unit is now pursuing following a spike in hospital admissions.<\/p>\n\n\n\n

Read together, that is a description of poorly executed platysma treatment. Higher unit counts than upper-face work, anatomical proximity to the muscles of swallowing, and a strong chance the product being used is not licensed for the site.<\/p>\n\n\n\n

Symptoms of iatrogenic botulism typically appear between four and eight days after treatment but can take up to four weeks. Patients must be told what to look for: severe drooping of the upper eyelids, difficulty breathing, slurred speech and difficulty swallowing. That advice is an emergency instruction, not a caution, and it belongs in written aftercare rather than a verbal mention on the way out.<\/p>\n\n\n\n

Prescribers carry a specific duty here. Anyone they direct to administer the product must follow the prescription and be familiar with this update. Suspected reactions go to the Yellow Card scheme<\/mark><\/a>, and suspected cases should be managed in line with UKHSA guidance on the clinical management of iatrogenic botulism<\/mark><\/a>.<\/p>\n\n\n\n

Complications after botulinum toxin injections to the neck<\/h2>\n\n\n\n

The adverse event profile in the licensed regimen is reassuring when the protocol is followed. In the first treatment cycle of the platysma trials, adverse events considered treatment-related occurred in 4.7% of patients across the 26, 31 and 36 Unit groups, against 5.0% in the placebo group.<\/p>\n\n\n\n

That figure describes correct dosing at correct depth by trained injectors. The complications that concern practitioners in practice come from deviation. Dysphagia and neck weakness follow product reaching the strap muscles or deeper cervical musculature, usually through placement that is too deep, too close to the mandibular border, or at doses beyond those studied. Dysphonia can follow the same mechanism.<\/p>\n\n\n\n

Prevention is largely mechanical. Keep placement superficial. Pinch to isolate. Respect the 1 cm margin below the mandible. Do not stack a platysma treatment onto a high total dose elsewhere in the same session without accounting for cumulative exposure.<\/p>\n\n\n\n

If a patient reports swallowing or breathing difficulty, that is an emergency referral rather than a review appointment. Anything less severe still needs same-day assessment, documentation and a Yellow Card report. Practices without an escalation route should establish one before offering the treatment, not after, whether that is a named local colleague or an on-demand complications consultant for aesthetic practitioners<\/mark><\/a>.<\/p>\n\n\n\n

Confirm the indication before the next neck consultation<\/h2>\n\n\n\n

Check which authorisation the product in the fridge actually carries, because the platysma indication belongs to one product and not to the class. If the intention is to treat off-label with a different toxin, arrange that decision with a prescriber for aesthetic practitioners<\/mark><\/a> in advance and record the justification, and put the botulism warning symptoms into written aftercare form<\/mark><\/a> rather than relying on a verbal mention<\/p>\n\n\n\n

FAQs<\/h2>\n\n\n
\n
\n
\n

How many units of Botox are used for platysma bands?<\/strong><\/p>\n

\n\n

The licensed regimen uses 26, 31 or 36 Allergan Units depending on how many vertical bands require treatment, distributed between the upper platysma and the bands themselves. Units are specific to this product and cannot be converted to any other botulinum toxin preparation.<\/p>\n\n<\/div>\n<\/div>\n

\n

How long does treatment of platysma bands last?<\/strong><\/p>\n

\n\n

Improvement in the pivotal studies remained significantly greater than placebo through day 120, which is the point at which the studies ended. Onset is not immediate, with the first assessed timepoint at day 14.<\/p>\n\n<\/div>\n<\/div>\n

\n

Does treating the platysma improve the jawline?<\/strong><\/p>\n

\n\n

It can, because the platysma exerts a downward pull on the lower face, and the licensed protocol includes injection into the upper platysma below the jawline. It does not correct submental fat or skin laxity, so patients whose main issue is either of those need a different conversation.<\/p>\n\n<\/div>\n<\/div>\n

\n

Is neck toxin treatment safe?<\/strong><\/p>\n

\n\n

In the licensed regimen, treatment-related adverse events occurred in 4.7% of trial patients compared with 5.0% on placebo. Safety depends heavily on correct depth, correct dose and staying clear of the mandibular border, and the MHRA specifically flags high doses and off-label sites as risk factors.<\/p>\n\n<\/div>\n<\/div>\n

\n

What is the main downside of treating platysma bands?<\/strong><\/p>\n

\n\n

The most significant risks are difficulty swallowing and neck weakness caused by product spreading beyond the intended muscle. Patients with existing swallowing difficulties or neurological conditions are a higher-risk group and should be identified before treatment rather than after.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Ask a room of injectors at any aesthetic clinic whether neck work with botulinum toxin is off-label and most hands go up. That answer was correct until May 2025 and has been wrong ever since, which means a significant number of practitioners are either avoiding a treatment they could legitimately offer, or offering it while […]<\/p>\n","protected":false},"author":6,"featured_media":12944,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"footnotes":""},"categories":[20],"tags":[12,65,10,14,227],"class_list":["post-12938","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-aesthetics","tag-aesthetics","tag-botox","tag-medical-practitioners","tag-treatment","tag-uk"],"_links":{"self":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12938","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/comments?post=12938"}],"version-history":[{"count":3,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12938\/revisions"}],"predecessor-version":[{"id":12948,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/posts\/12938\/revisions\/12948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/media\/12944"}],"wp:attachment":[{"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/media?parent=12938"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/categories?post=12938"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/facesconsent.com\/blog\/wp-json\/wp\/v2\/tags?post=12938"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}